Morgan E, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72:338–44.

Article  PubMed  Google Scholar 

Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5:1–30.

Google Scholar 

Jiang Y, et al. Global pattern and trends of colorectal cancer survival: a systematic review of population-based registration data. Cancer Biol Med. 2022;19:175–86.

Google Scholar 

Hossain MdS, et al. Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers. 2022;14:1732.

Article  PubMed  PubMed Central  Google Scholar 

Douillard J-Y, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023–34.

Article  CAS  PubMed  Google Scholar 

Ciardiello F, et al. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022;72:372–401.

Article  PubMed  Google Scholar 

Cervantes A, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2023;34:10–32.

Article  CAS  Google Scholar 

Santini D, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol Off J Eur Soc Med Oncol. 2012;23:2313–8.

Article  CAS  Google Scholar 

Dienstmann, R., Salazar, R. &Tabernero, J. Overcoming resistance to anti-EGFR therapy in colorectal cancer. Am Soc Clin Oncol Educ Book 2015;e149–e156 https://doi.org/10.14694/EdBook_AM.2015.35.e149

Siravegna G, et al. Monitoring clonal evolution and resistance to EGFR blockade in the blood of metastatic colorectal cancer patients. Nat Med. 2015;21:795.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morelli MP, et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol. 2015;26:731.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martini G, et al. Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? Cancer Treat Rev. 2020;86:102023.

Article  CAS  PubMed  Google Scholar 

Martinelli E, et al. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. Ann Oncol Off J Eur Soc Med Oncol. 2020;31:30–40.

Article  CAS  Google Scholar 

Parseghian CM, et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol Off J Eur Soc Med Oncol. 2019;30:243–9.

Article  CAS  Google Scholar 

Tonini G, Imperatori M, Vincenzi B, Frezza AM, Santini D. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Cancer Res. 2013;32(1):92.

Article  PubMed  PubMed Central  Google Scholar 

Vlachou MS, et al. Plasma ctDNAras status selects patients for Anti-EGFR treatment rechallenge in metastatic colorectal cancer: a meta-analysis. Exp Oncol. 2021;43:252–6.

Article  CAS  PubMed  Google Scholar 

Mauri G, et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat Rev. 2019;73:41–53.

Article  CAS  PubMed  Google Scholar 

Higgins JPT, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

Article  PubMed  PubMed Central  Google Scholar 

Sterne JA, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Article  PubMed  PubMed Central  Google Scholar 

Barker TH, et al. Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence. BMC Med Res Methodol. 2021;21:189.

Article  PubMed  PubMed Central  Google Scholar 

One‐sample aggregate data meta‐analysis of medians - McGrath - 2019 - Statistics in Medicine - Wiley Online Library.https://onlinelibrary.wiley.com/doi/abs/https://doi.org/10.1002/sim.8013.

Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.

Article  PubMed  Google Scholar 

Aparicio J, et al. Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17–01). Clin Transl Oncol. 2022;24:2155–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cremolini C, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 2019;5:343–50.

Article  PubMed  Google Scholar 

Fora AA, et al. A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan. Oncol Switz. 2013;84:210–3.

Article  CAS  Google Scholar 

Izawa N, et al. A phase II trial of trifluridine/tipiracil in combination with cetuximab rechallenge in patients with RAS wild-type mCRC refractory to prior anti-EGFR antibodies: WJOG8916G Trial. Target Oncol. 2023;18:369–81.

Article  PubMed  Google Scholar 

Kajitani T, et al. Anti-epidermal growth factor receptor antibody readministration in chemorefractory metastatic colorectal cancer. Anticancer Res. 2017;37:6459–68.

CAS  PubMed  Google Scholar 

Masuishi T, et al. Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08. Br J Cancer. 2020. https://doi.org/10.1038/s41416-020-01042-w.

Article  PubMed  PubMed Central  Google Scholar 

Nakajima TE, et al. Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3–1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer. Invest New Drugs. 2020;38:410–8.

Article  CAS  PubMed  Google Scholar 

Napolitano S, et al. Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: overall survival and subgroup analysis of the randomized phase II VELO trial. Int J Cancer. 2023;153:1520–8.

Article  CAS  PubMed  Google Scholar 

Quan M, et al. China special issue on gastrointestinal tumors-Cetuximab retreatment plus camrelizumab and liposomal irinotecan in patients with RAS wild-type metastatic colorectal cancer: cohort B of the phase II CRACK study. Int J Cancer. 2023;153:1877–84.

Article  CAS  PubMed  Google Scholar 

Sartore-Bianchi A, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022;28:1612–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sorah JD, et al. Phase II single-arm study of palbociclib and cetuximab rechallenge in patients with KRAS/NRAS/BRAF wild-type colorectal cancer. Oncologist. 2022;27:E1006–930.

Article  Google Scholar 

Tsuji A, et al. Phase II study of third-line cetuximab rechallenge in patients with metastatic wild-type K-RAS colorectal cancer who achieved a clinical benefit in response to first-line cetuximab plus chemotherapy (JACCRO CC-08). Ann Oncol. 2016;27:vi168.

Article  Google Scholar 

Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression—implications for drug resistance. Nat Rev Clin Oncol. 2013;10:571–87.